Krystal Biotech (KRYS) Competitors

Krystal Biotech (NASDAQ:KRYS) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, community ranking, risk and media sentiment.

Does the media prefer KRYS or GMAB?

In the previous week, Genmab A/S had 1 more articles in the media than Krystal Biotech. MarketBeat recorded 8 mentions for Genmab A/S and 7 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.31 beat Genmab A/S's score of 0.39 indicating that Krystal Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do insiders & institutionals believe in KRYS or GMAB?

86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 7.1% of Genmab A/S shares are held by institutional investors. 13.7% of Krystal Biotech shares are held by insiders. Comparatively, 1.5% of Genmab A/S shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Is KRYS or GMAB more profitable?

Genmab A/S has a net margin of 36.30% compared to Krystal Biotech's net margin of 30.69%. Genmab A/S's return on equity of 16.78% beat Krystal Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	30.69%	11.41%	10.40%
Genmab A/S	36.30%	16.78%	13.79%

Do analysts prefer KRYS or GMAB?

Krystal Biotech currently has a consensus price target of $211.13, indicating a potential upside of 54.03%. Genmab A/S has a consensus price target of $39.17, indicating a potential upside of 71.63%. Given Genmab A/S's higher probable upside, analysts plainly believe Genmab A/S is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00
Genmab A/S	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

Which has more volatility & risk, KRYS or GMAB?

Krystal Biotech has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.96, indicating that its share price is 4% less volatile than the S&P 500.

Does the MarketBeat Community believe in KRYS or GMAB?

Krystal Biotech received 132 more outperform votes than Genmab A/S when rated by MarketBeat users. Likewise, 67.80% of users gave Krystal Biotech an outperform vote while only 62.55% of users gave Genmab A/S an outperform vote.

Company	Underperform	Outperform
Krystal Biotech	Outperform Votes 299 67.80%	Underperform Votes 142 32.20%
Genmab A/S	Outperform Votes 167 62.55%	Underperform Votes 100 37.45%

Which has better earnings & valuation, KRYS or GMAB?

Genmab A/S has higher revenue and earnings than Krystal Biotech. Genmab A/S is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$333.45M	11.88	$10.93M	$4.16	32.95
Genmab A/S	$3.12B	4.70	$1.14B	$1.76	12.97

Summary

Krystal Biotech and Genmab A/S tied by winning 9 of the 18 factors compared between the two stocks.